XML 19 R9.htm IDEA: XBRL DOCUMENT
v3.25.3

Revenue (Notes) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended
--- | --- | ---
Sep. 28, 2025 | Sep. 29, 2024 | Sep. 28, 2025 | Sep. 29, 2024
Disaggregation of Revenue [Line Items] |  |  |  |
Revenue from Contract with Customer [Text Block] |  |  | Revenue Disaggregation of revenue Disaggregated revenue by primary geographical markets and major goods and service lines are as follows:
| Reportable Segments
| Three Months Ended
| September 28, 2025 |  | September 29, 2024
| Life Sciences |  | Diagnostics |  | Total |  | Life Sciences |  | Diagnostics |  | Total
| (In thousands)
Primary geographical markets |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 178,087 |  |  | $ | 129,190 |  |  | $ | 307,277 |  |  | $ | 185,476 |  |  | $ | 116,849 |  |  | $ | 302,325 |
Europe | 83,332 |  |  | 119,065 |  |  | 202,397 |  |  | 75,115 |  |  | 106,923 |  |  | 182,038 |
Asia | 81,403 |  |  | 107,872 |  |  | 189,275 |  |  | 78,209 |  |  | 121,477 |  |  | 199,686 |
| $ | 342,822 |  |  | $ | 356,127 |  |  | $ | 698,949 |  |  | $ | 338,800 |  |  | $ | 345,249 |  |  | $ | 684,049 |
Major goods/service lines |  |  |  |  |  |  |  |  |  |  |
Life Sciences Solutions | $ | 290,541 |  |  | $ | — |  |  | $ | 290,541 |  |  | $ | 295,455 |  |  | $ | — |  |  | $ | 295,455 |
Software | 52,281 |  |  | — |  |  | 52,281 |  |  | 43,345 |  |  | — |  |  | 43,345 |
Immunodiagnostics | — |  |  | 212,739 |  |  | 212,739 |  |  | — |  |  | 211,566 |  |  | 211,566 |
Reproductive health | — |  |  | 143,388 |  |  | 143,388 |  |  | — |  |  | 133,683 |  |  | 133,683 |
| $ | 342,822 |  |  | $ | 356,127 |  |  | $ | 698,949 |  |  | $ | 338,800 |  |  | $ | 345,249 |  |  | $ | 684,049 |
| Reportable Segments
| Nine Months Ended
| September 28, 2025 |  | September 29, 2024
| Life Sciences |  | Diagnostics |  | Total |  | Life Sciences |  | Diagnostics |  | Total
| (In thousands)
Primary geographical markets |  |  |  |  |  |  |  |  |  |  |
Americas | $ | 559,437 |  |  | $ | 376,049 |  |  | $ | 935,486 |  |  | $ | 551,843 |  |  | $ | 352,619 |  |  | $ | 904,462 |
Europe | 243,652 |  |  | 344,169 |  |  | 587,821 |  |  | 227,123 |  |  | 318,065 |  |  | 545,188 |
Asia | 246,026 |  |  | 314,662 |  |  | 560,688 |  |  | 244,873 |  |  | 331,131 |  |  | 576,004 |
| $ | 1,049,115 |  |  | $ | 1,034,880 |  |  | $ | 2,083,995 |  |  | $ | 1,023,839 |  |  | $ | 1,001,815 |  |  | $ | 2,025,654 |
Major goods/service lines |  |  |  |  |  |  |  |  |  |  |
Life Sciences Solutions | $ | 875,046 |  |  | $ | — |  |  | $ | 875,046 |  |  | $ | 884,849 |  |  | $ | — |  |  | $ | 884,849 |
Software | 174,069 |  |  | — |  |  | 174,069 |  |  | 138,990 |  |  | — |  |  | 138,990 |
Immunodiagnostics | — |  |  | 629,119 |  |  | 629,119 |  |  | — |  |  | 613,479 |  |  | 613,479 |
Reproductive health | — |  |  | 405,761 |  |  | 405,761 |  |  | — |  |  | 388,336 |  |  | 388,336 |
| $ | 1,049,115 |  |  | $ | 1,034,880 |  |  | $ | 2,083,995 |  |  | $ | 1,023,839 |  |  | $ | 1,001,815 |  |  | $ | 2,025,654 |
Contract Balances Unbilled receivable and Contract assets: The timing of revenue recognition may differ from the timing of customer billing. When revenue is recognized prior to billing and the right to the amount due from customers is conditioned only on the passage of time, the Company records an unbilled receivable on its consolidated balance sheets. The unbilled receivables are classified as either current in “Accounts receivable, net” or as long-term in “Other assets, net” in the condensed consolidated balance sheets. Unbilled receivables totaled $95.5 million and $80.6 million at September 28, 2025 and December 29, 2024, respectively, primarily related to the Life Sciences software business. The Company had no material contract assets as of September 28, 2025 and December 29, 2024. Deferred revenue and Customer deposits: Deferred revenue is recorded when revenue is recognized subsequent to customer invoicing. Deferred revenue is classified as either current in “Accrued expenses and other current liabilities” or as long-term in “Other long-term liabilities” in the condensed consolidated balance sheets based on the timing of when the Company expects to recognize revenue. Substantially all of the deferred revenue is expected to be recognized in revenue within 12 months of the balance sheet date, and has been classified within accrued expenses and other current liabilities. The deferred revenue balance is primarily related to the Company’s software as a service offerings, maintenance contracts and prepaid storage arrangements. Deferred revenue totaled $224.0 million and $212.8 million at September 28, 2025 and December 29, 2024, respectively. The Company also had customer deposits received in advance of the transfer of control totaling $19.5 million at September 28, 2025 and December 29, 2024. The Company expects that these customer deposits will be recognized in revenue within three months of the balance sheet date. Transaction price allocated to the remaining performance obligations The Company applies the practical expedient and does not disclose information about remaining performance obligations that have original expected durations of one year or less. The estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the period are not material to the Company. The remaining performance obligations primarily include noncancelable purchase orders, noncancelable software subscriptions and cloud service contracts and long-term prepaid storage contracts. |
Segment revenue | $ 698,949 | $ 684,049 | $ 2,083,995 | $ 2,025,654
Americas [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Segment revenue | 307,277 | 302,325 | 935,486 | 904,462
Europe [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Segment revenue | 202,397 | 182,038 | 587,821 | 545,188
Asia [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Segment revenue | 189,275 | 199,686 | 560,688 | 576,004
Life Sciences Solutions [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Segment revenue | 290,541 | 295,455 | 875,046 | 884,849
Software [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Segment revenue | 52,281 | 43,345 | 174,069 | 138,990
Reproductive health [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Segment revenue | 143,388 | 133,683 | 405,761 | 388,336
Applied genomics [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Segment revenue |  | 684,049 |  | 2,025,654
Immunodiagnostics [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Segment revenue | 212,739 | 211,566 | 629,119 | 613,479
Diagnostics [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Segment revenue | 356,127 | 345,249 | 1,034,880 | 1,001,815
Diagnostics [Member] | Americas [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Segment revenue | 129,190 | 116,849 | 376,049 | 352,619
Diagnostics [Member] | Europe [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Segment revenue | 119,065 | 106,923 | 344,169 | 318,065
Diagnostics [Member] | Asia [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Segment revenue | 107,872 | 121,477 | 314,662 | 331,131
Diagnostics [Member] | Life Sciences Solutions [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Segment revenue | 0 | 0 | 0 | 0
Diagnostics [Member] | Software [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Segment revenue | 0 | 0 | 0 | 0
Diagnostics [Member] | Reproductive health [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Segment revenue | 143,388 | 133,683 | 405,761 | 388,336
Diagnostics [Member] | Immunodiagnostics [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Segment revenue | 212,739 | 211,566 | 629,119 | 613,479
Life Sciences [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Segment revenue | 342,822 | 338,800 | 1,049,115 | 1,023,839
Life Sciences [Member] | Americas [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Segment revenue | 178,087 | 185,476 | 559,437 | 551,843
Life Sciences [Member] | Europe [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Segment revenue | 83,332 | 75,115 | 243,652 | 227,123
Life Sciences [Member] | Asia [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Segment revenue | 81,403 | 78,209 | 246,026 | 244,873
Life Sciences [Member] | Life Sciences Solutions [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Segment revenue | 290,541 | 295,455 | 875,046 | 884,849
Life Sciences [Member] | Software [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Segment revenue | 52,281 | 43,345 | 174,069 | 138,990
Life Sciences [Member] | Reproductive health [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Segment revenue | 0 | 0 | 0 | 0
Life Sciences [Member] | Immunodiagnostics [Member] |  |  |  |
Disaggregation of Revenue [Line Items] |  |  |  |
Segment revenue | $ 0 | $ 0 | $ 0 | $ 0

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details
Name: | us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details
Name: | us-gaap_RevenueFromContractWithCustomerTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=srt_AmericasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_EuropeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=srt_AsiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | revv_MajorGoodsserviceLinesAxis=revv_LifeSciencesSolutionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | revv_MajorGoodsserviceLinesAxis=revv_SoftwareMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | revv_MajorGoodsserviceLinesAxis=revv_ReproductiveHealthMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | revv_MajorGoodsserviceLinesAxis=revv_AppliedGenomicsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | revv_MajorGoodsserviceLinesAxis=revv_ImmunodiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=revv_DiagnosticsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=revv_LifeSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |